Takeda and NuBiyota announce microbiome therapeutic research collaboration

Takeda has allied with NuBiyota on the development of new microbial ecosystem therapeutic products for gastroenterology indications where a high unmet medical need exists.

The companies will utilise NuBiyota's microbiome platform to advance a new range of oral microbial consortia products. The research will examine how microbial consortia and microbiome-derived bioactives can be harnessed for treatment of gastrointestinal disease.

NuBiyota's Microbial Ecosystem Therapeutic is a clinic-ready microbial consortia designed to offer an entry point for the clinical evaluation of microbiome-based therapeutics, making it easier to enhance understanding of the role of microbiota in various diseases.

In exchange for the use of this technology, NuBiyota will receive an upfront payment and is eligible for milestone-based development, regulatory and commercial fees, plus tiered royalties based on net sales. 

Dr Asit Parikh, head of Takeda's gastroenterology therapeutic area unit, said: "We are excited to partner with NuBiyota, as this collaboration reinforces Takeda's long-term commitment to unmet medical need in gastroenterology and adds to our other microbiome-related partnerships."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.